BCAX
Bicara Therapeutics Inc.
Key Financials
Net Income
$-137950000
↓ 102.9%
Operating Income
$-155604000
↓ 88.9%
EPS (Diluted)
$-2.52
↑ 37.8%
Shareholders' Equity
$401.5M
↓ 18.4%
Total Liabilities
$29.5M
↑ 63.0%
Total Assets
$431.0M
↓ 15.5%
Cash & Equivalents
$96.7M
↓ 80.3%
Operating Cash Flow
$-106834000.00
↓ 42.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 8/14/2026 | View on SEC |
| 3 | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| 4 | 8/12/2026 | View on SEC |
| 4 | 8/12/2026 | View on SEC |
| 4 | 8/12/2026 | View on SEC |
| S-8 | 8/11/2026 | View on SEC |
| 10-Q | 8/11/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 144 | 8/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BCAX |
| Company Name | Bicara Therapeutics Inc. |
| CIK | 2023658 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-468-4219 |